Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27142048
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the
Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions
#MMPMID27142048
Sexton T
; Wallace EL
; Smyth SS
Curr Cardiol Rev
2016[]; 12
(4
): 324-329
PMID27142048
show ga
HMG CoA reductase inhibitors, or statins, are standard of care for preventing
cardiovascular disease in at-risk populations. Statins are a well-established
therapy proven to reduce long-term cardiovascular mortality and morbidity for
prevention of secondary cardiovascular events and have become
guidelinerecommended therapy following acute myocardial infarction. Emerging data
from clinical trials over the last decade indicates that statin therapy may
provide broad beneficial effects beyond their primary lipid lowering mechanisms.
In coronary heart disease, statins have demonstrated a unique ability to target
several cellular pathways, which appear to play an underappreciated role in acute
inflammation and subsequent thrombosis. Herein, we review the potential
mechanisms where statins may act as antithrombotic agents in the setting of acute
coronary syndromes and discuss the clinical implications of these findings.
free
free
free
